Osimertinib for Japanese patients with T790M‐positive advanced non‐small‐cell lung cancer: A pooled subgroup analysis

Epidermal growth factor receptor (EGFR)‐tyrosine kinase inhibitors (TKIs) are the standard of care for non‐small‐cell lung cancer (NSCLC) patients harboring EGFR mutations. However, almost all patients develop resistance after approximately 1 y of treatment, with >50% of cases due to the T790M se...

Descripción completa

Detalles Bibliográficos
Autores principales: Hirashima, Tomonori, Satouchi, Miyako, Hida, Toyoaki, Nishio, Makoto, Kato, Terufumi, Sakai, Hiroshi, Imamura, Fumio, Kiura, Katsuyuki, Okamoto, Isamu, Kasahara, Kazuo, Uchida, Hirohiko, Vowler, Sarah L., Mitsudomi, Tetsuya
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2019
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6726692/
https://www.ncbi.nlm.nih.gov/pubmed/31265163
http://dx.doi.org/10.1111/cas.14120

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6726692/
https://www.ncbi.nlm.nih.gov/pubmed/31265163
http://dx.doi.org/10.1111/cas.14120

Ejemplares similares